People
Michael is a Senior Associate in the Tax Department based in London. Michael has extensive knowledge in advising clients on tax projects globally. His practice focuses on complex transactional and advisory matters.
Michael advises clients on cross-border financings, acting for a variety of financial institutions, as well as alternate credit advisors, cross-border mergers and acquisitions (with a particular focus on the private equity sector) and institutions on the implementation of employee reward schemes, both for large corporates and private equity sponsors.
Michael also has experience of HMRC enquiries and working with clients and HMRC to reach mutually satisfactory outcomes.
Michael's experience involves work with Francisco Partners, Blackstone Credit, Resurgens Technology Partners and Barings Asset Management
England and Wales
October 31, 2025
King & Spalding Advises Abry Partners On Financing For AA Ireland Investment
October 30, 2025
Ripple Labs Inc. Acquires Palisade Financial Group Ltd.
August 7, 2025
K&S advises Oxford Biomedica PLC on its $125M secured loan facility provided by Oaktree Capital Management
Dow on the US$ 125 million sale of its 50% ownership in its DowAksa joint venture, a manufacturer of carbon fire and carbon fibre composites, to Aksa Akrilik Kimya Sanayii A.S. (Aksa), with primary operations in Turkey.
October 31, 2025
King & Spalding Advises Abry Partners On Financing For AA Ireland Investment
October 30, 2025
Ripple Labs Inc. Acquires Palisade Financial Group Ltd.
August 7, 2025
K&S advises Oxford Biomedica PLC on its $125M secured loan facility provided by Oaktree Capital Management
Dow on the US$ 125 million sale of its 50% ownership in its DowAksa joint venture, a manufacturer of carbon fire and carbon fibre composites, to Aksa Akrilik Kimya Sanayii A.S. (Aksa), with primary operations in Turkey.
October 31, 2025
King & Spalding Advises Abry Partners On Financing For AA Ireland Investment
October 30, 2025
Ripple Labs Inc. Acquires Palisade Financial Group Ltd.
August 7, 2025
K&S advises Oxford Biomedica PLC on its $125M secured loan facility provided by Oaktree Capital Management
England and Wales